In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of Covid-19.
This is the first update on the pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for the treatment of COVID-19. Following the original Rapid Collaborative Review – PTRCR15, published in September 2020, evidence gaps were identified, such as the need for adequately powered RCTs with clinically relevant outcomes, including all-cause mortality, the additional need for and duration of mechanical ventilation, additional need for and duration of supplemental oxygen and duration of hospitalisation. The subsequent publication of results from two RCTs, including the final report of the ACTT-1 trial and the preliminary report of the WHO SOLIDARITY trial, as well as data from two living clinical guidelines, are used to summarise the most recent evidence to further support the local production of national/regional HTA reports.
For any questions regarding the Rapid Collaborative Review, please contact eunethta@zinl.nl.
Please find the review here:
PTRCR15 – First update of the Rapid Collaborative Review, December 2020
PTRCR15 – Original Rapid Collaborative Review: PICO and Evidence Gaps, September 2020
